News
Cardiff Oncology Advances Onvansertib Phase 3 for RAS-Mutated Metastatic Colorectal Cancer
2+ hour, 36+ min ago (400+ words) The Clinical Trial Vanguard Cardiff Oncology Advances Onvansertib Phase 3 for RAS-Mutated Metastatic Colorectal Cancer A 72. 2% confirmed objective response rate in first-line RAS-mutated metastatic colorectal cancer " against 43. 2% across combined standard-of-care arms " is the number Cardiff Oncology carried into its End-of-Phase 2 FDA…...
NBTXR3 Shows 57% Complete Response Rate in Stage III Lung Cancer Study
2+ hour, 36+ min ago (393+ words) The Clinical Trial Vanguard NBTXR3 Shows 57% Complete Response Rate in Stage III Lung Cancer Study A 57% complete response rate in stage III unresectable NSCLC stops you cold " the current standard of care, concurrent chemoradiation plus durvalumab, produces complete responses in fewer…...
Uro Gen's UGN-103 Shows 94. 5% Response Rate in Phase 3 NMIBC Trial
2+ hour, 37+ min ago (398+ words) The Clinical Trial Vanguard Uro Gen's UGN-103 Shows 94. 5% Response Rate in Phase 3 NMIBC Trial A 94. 5% six-month duration of response sounds like a clean win, but the more revealing number sits two percentage points lower: ZUSDURI's own pivotal ENVISION trial posted…...
Simufilam Shows Promise in Preclinical TSC-Related Epilepsy Study
9+ mon, 1+ week ago (59+ words) Cassava Sciences reports positive preclinical data for simufilam in a tuberous sclerosis complex (TSC) mouse model, specifically demonstrating anti-seizure activity. The study, conducted in collaboration with the TSC Alliance, utilized the established Tsc1-knockout model. This positive preclinical signal represents a…...
Alumis Reports 68% PASI 90 Response for Envudeucitinib in Psoriasis Trial
2+ hour, 35+ min ago (405+ words) The Clinical Trial Vanguard Alumis Reports 68% PASI 90 Response for Envudeucitinib in Psoriasis Trial Deucravacitinib captured roughly 68% PASI 90 response rates in pivotal trials and became the first oral TYK2 inhibitor approved for plaque psoriasis " yet Alumis is now reporting identical 68. 0% PASI 90 figures…...
The e COA Vendor Stack You Built Is Already Obsolete
2+ hour, 39+ min ago (874+ words) The Clinical Trial Vanguard The e COA Vendor Stack You Built Is Already Obsolete Picture a coordinator at a mid-size academic site running three concurrent oncology trials. She has a Signant Health e COA device for patient-reported outcomes on the…...
The TOBRA Trial Just Killed a Widely Used Surgical Assumption " And Most Orthopedic Programs Haven't Noticed Yet
2+ hour, 40+ min ago (666+ words) The Clinical Trial Vanguard The TOBRA Trial Just Killed a Widely Used Surgical Assumption " And Most Orthopedic Programs Haven't Noticed Yet Walk into almost any Level I trauma center today and you will find the same ritual before wound closure…...
Regeneron's Fianlimab Misses Statistical Significance in Melanoma Trial
2+ hour, 38+ min ago (394+ words) The Clinical Trial Vanguard Regeneron's Fianlimab Misses Statistical Significance in Melanoma Trial A 5. 1-month improvement in median progression-free survival " from 6. 4 months on pembrolizumab monotherapy to 11. 5 months on the high-dose fianlimab-cemiplimab combination " failed to cross the threshold of statistical significance, with…...
Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy
2+ hour, 34+ min ago (468+ words) The Clinical Trial Vanguard Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy Half of 22 heavily pretreated R/R AML patients achieved a composite complete remission when they received SENTI-202 doses manufactured from cells bearing a specific…...
Alumis" Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial
1+ day, 2+ hour ago (405+ words) The Clinical Trial Vanguard Alumis" Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial Sixty-eight percent of patients with moderate-to-severe plaque psoriasis achieved PASI 90 at Week 24 in the ONWARD1 trial " a number that lands meaningfully above the roughly 5055% PASI 90 benchmarks typically seen in…...